secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001645113-26-000007
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement
--------------------------------------------------------------------------------

- CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.
- Company estimates approximately $13 million per month in lost revenue from CMS payors until privileges are reinstated.
- NovoCure has filed a Corrective Action Plan and expects reinstatement, but cannot predict timing with certainty.
- Company continues to provide services to existing and new patients; will attempt to bill for services during reinstatement.
- Financial impact and ultimate outcome cannot be determined at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000007/0001645113-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000007/nvcr-20260130.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer